Key result
Vorapaxar reduced the hazard of a first myocardial infarction of any type by 12% (HR 0.88; 95% CI 0.79-0.98; P=0.021) compared with placebo in patients with high-risk NSTE ACS.
Why the study?
Does vorapaxar reduce myocardial infarction in patients with high-risk non-ST-segment elevation acute coronary syndromes?
Population
12,944 patients with high-risk non-ST-segment elevation acute coronary syndromes (NSTE ACS)
Comparison
Vorapaxar (platelet protease-activated… vs Placebo
Design
RCT, blinded
Follow-up
median 502 days
Authors
Loading...
Supports vorapaxar for MI prevention in high-risk NSTE ACS; extends TRA·CER RCT evidence on PAR-1 inhibition.
RCT (n=12,944)
Blinded
Does vorapaxar reduce myocardial infarction in patients with high-risk non-ST-segment elevation acute coronary syndromes?
Hazard Ratio: 0.88 (95% CI 0.79–0.98)
p-value: p=0.021
In an exploratory analysis of the TRA·CER trial, vorapaxar significantly reduced the incidence of first and total myocardial infarctions, primarily driven by a reduction in type 1 spontaneous MIs, in patients with high-risk NSTE ACS.
Leonardi et al. (2013) conducted an RCT in high-risk non-ST-segment elevation acute coronary syndromes (NSTE ACS) (n=12,944). Vorapaxar vs. Placebo was evaluated on first myocardial infarction of any type (HR 0.88, 95% CI 0.79-0.98, p=0.021). Vorapaxar reduced the hazard of a first myocardial infarction of any type by 12% (HR 0.88; 95% CI 0.79-0.98; P=0.021) compared with placebo in patients with high-risk NSTE ACS.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: